REAL WORLD EFFECTIVENESS AND SAFETY OF OZANIMOD: INITIAL RESULTS FROM A LARGE TERTIARY CENTER

被引:0
|
作者
Cohen, Nathaniel
Choden, Tenzin
Choi, David
Cleveland, Noa
Cohen, Russell
Dalal, Sushila
Sakuraba, Atsushi
Hanan, Ira
Rubin, David
机构
关键词
D O I
10.1093/ibd/izac015.175
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
引用
收藏
页码:S109 / S109
页数:1
相关论文
共 50 条
  • [41] Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
    Hong, Simon J.
    Cleveland, Noa Krugliak
    Akiyama, Shintaro
    Zullow, Samantha
    Yi, Yangtian
    Shaffer, Seth R.
    Malter, Lisa B.
    Axelrad, Jordan E.
    Chang, Shannon
    Hudesman, David P.
    Rubin, David T.
    CROHNS & COLITIS 360, 2021, 3 (01) : 1 - 8
  • [42] Real-world effectiveness of fremanezumab in patients with refractory migraine from a US tertiary headache center who switched from erenumab
    Yuan, H.
    Hopkins, M.
    Driessen, M. T.
    Krasenbaum, L. J.
    Seminerio, M. J.
    Marmura, M. J.
    HEADACHE, 2022, 62 : 156 - 157
  • [43] Treatment of Chronic Pouchitis With Tofacitinib: Real World Experience From a Tertiary Center
    Akiyama, Shintaro
    Traboulsi, Cindy
    Rai, Victoria
    Dalal, Sushila R.
    Rubin, David T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1679 - S1680
  • [44] Real World Ocrelizumab Experience of a Tertiary Center in Turkey
    Arslan, Doruk
    Acar-Ozen, Nazire Pinar
    Karabudak, Rana
    Tuncer, Asli
    NEUROLOGY, 2021, 96 (15)
  • [45] Stop Imatinib: Real World Data from a Tertiary Care Center in India
    Kataria, Babita
    Upadhyay, Avinash
    Kumar, Lalit
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S301 - S301
  • [46] Comparing initial LABA-ICS inhalers in COPD: Real-world effectiveness and safety
    Suissa, Samy
    Dell'Aniello, Sophie
    Ernst, Pierre
    RESPIRATORY MEDICINE, 2021, 189
  • [47] DOACS EFFECTIVENESS AND SAFETY: FURTHER CONFIRMATIONS FROM REAL WORLD EXPERIENCE
    Ciavolella, M.
    Cianfrocca, M.
    Braccioli, C.
    Ceccacci, R.
    Bisegni, S.
    De Carolis, M.
    Ciavolella, F.
    Bidolli, F.
    Frongillo, D.
    Sarli, G.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 (SUPPL C)
  • [48] Risankizumab Effectiveness in Ustekinumab-naive and Ustekinumab-experienced Patients with Crohn's Disease- Real-world Data from a Large Tertiary Center
    Zinger, A.
    Choi, D.
    Choi, N.
    Fear, E.
    Fine, Z.
    Cohen, R. D.
    Dalal, S. R.
    Cleveland, N. Krugliak
    Pekow, J.
    Rubin, D. T.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1565 - I1565
  • [49] Real-world effectiveness and safety of alirocumab
    Mondelo Garcia, C.
    Garcia Queiruga, M.
    Balea Filgueiras, J.
    Fernandez Bargiela, N.
    Gimenez Arufe, V.
    Fernandez Oliveira, C.
    Martin Herranz, M. I.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (01) : 377 - 378
  • [50] The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium
    Johnson, Amanda M.
    Barsky, Maria
    Ahmed, Waseem
    Zullow, Samantha
    Galati, Jonathan
    Jairath, Vipul
    Narula, Neeraj
    Peerani, Farhad
    Click, Benjamin H.
    Coburn, Elliot S.
    Dang, ThucNhi Tran
    Gold, Stephanie
    Agrawal, Manasi
    Garg, Rajat
    Aggarwal, Manik
    Mohammad, Danah
    Halloran, Brendan
    Kochhar, Gursimran S.
    Todorowski, Hannah
    Ud Din, Nabeeha Mohy
    Izanec, James
    Teeple, Amanda
    Gasink, Chris
    Muser, Erik
    Ding, Zhijie
    Swaminath, Arun
    Lakhani, Komal
    Hogan, Dan
    Datta, Samit
    Ungaro, Ryan C.
    Boland, Brigid S.
    Bohm, Matthew
    Fischer, Monika
    Sagi, Sashidhar
    Afzali, Anita
    Ullman, Thomas
    Lawlor, Garrett
    Baumgart, Daniel C.
    Chang, Shannon
    Hudesman, David
    Lukin, Dana
    Scherl, Ellen J.
    Colombel, Jean-Frederic
    Sands, Bruce E.
    Siegel, Corey A.
    Regueiro, Miguel
    Sandborn, William J.
    Bruining, David
    Kane, Sunanda
    Loftus, Edward V., Jr.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (02): : 317 - 328